Versão HTML básica
379
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project – 2012
Rev Bras Hematol Hemoter. 2012;34(5):367-82
90. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al.
Trough imatinib plasma levels are associated with both cytogenetic
and molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 2007;109(8):3496-9. Comment in: Blood.
2007;110(5):1699-701; author reply 1701.
91. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW.
FISH for BCR-ABL on interphases of peripheral blood neutrophils but
not of unselected white cells correlates with bone marrow cytogenetics
in CML patients treated with imatinib. Leukemia. 2003;17(10):1925-9.
92. Mascarenhas CC, Cunha AF, Miranda EC, Zulli R, Silveira RA, Costa
FF, et al. New mutations detected by denaturing high performance liquid
chromatography during screening of exon 6 bcr-abl mutations in patients
with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leuk Lymphoma. 2009;50(7):1148-54.
93. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne
J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann
B, Niederwieser D, Fischer T; Chronic Leukaemia Working Party of
the European Group of Bone and Marrow Transplantation (EBMT).
Response to imatinib in patients who relapse after allogeneic stem
cell transplantation for chronic myeloid leukemia. Leukemia.
2003;17(9):1707-12. Comment in: Leukemia. 2003;17(9):1722.
94. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M,
Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A,
Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D,
Apperley JF; Chronic Leukemia Working Party of the EBMT. Outcomes
of reduced-intensity transplantation for chronic myeloid leukemia: an
analysis of prognostic factors from the ChronicLeukemia Working Party
of the EBMT. Blood. 2005;106(9):2969-76.
95. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, et al. Impact
of prior imatinib mesylate on the outcome of hematopoietic cell
transplantation for chronic myeloidleukemia. Blood. 2008;112(8):3500-7.
96. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, et
al. Imatinib use either pre- or post-allogeneic hematopoietic cell
transplantation (allo-HCT) does not increase cardiac toxicity in
chronic myelogenous leukemiapatients. Bone Marrow Transplant.
2009;44(3):169-74.
97. Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, et al. Imatinib combined
with myeloablative allogeneic hematopoietic stem cell transplantation
for advanced phases of chronic myeloid leukemia. Leuk Res.
2011;35(10):1307-11.
98. Jiang Q, Xu L, Liu D, Liu K, Chen S, Jiang B, et al. Imatinib mesylate
versus allogeneic hematopoietic stem cell transplantation for patients
with chronic myelogenous leukemia in the accelerated phase. Blood.
2011;117(11):3032-3040.
99. Boehm A, Walcherberger B, Sperr WR, Wöhrer S, Dieckmann K,
Rosenmayr A, et al.Improved outcome in patients with chronic
myelogenous leukemia after allogeneichematopoietic stem cell
transplantation over the past 25 years: a single-centerexperience. Biol
Blood Marrow Transplant. 2011;17(1):133-40.
100. Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, et
al. Second-generation tyrosine kinase inhibitors before allogeneic stem
cell transplantation in patients with chronic myeloid leukemia resistant
to imatinib. Leuk Res. 2010;34(2):143-7.
101. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al.
Imatinib is effective in children with previously untreated chronic
myelogenous leukemia in early chronic phase: results of the French
national phase IV trial. J Clin Oncol. 2011;29(20):2827-32.
102. Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, Dilloo D,
Kremens B, Kabisch H, Führer M, Zintl F, Göbel U, Klingebiel T. Klin
Padiatr. Allogeneic stem cell transplantation for pediatric and adolescent
patients with CML: results from the prospective trial CML-paed I. Klin
Padiatr. 2009;221(6):351-7.
Appendix 1
Search strategies and words used in to answer the clinical
questions:
PICO 1
What are the diagnostic criteria for chronic myeloid leukemia?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic,
Chronic OR Chronic Myelocytic Leukemia OR Leukemia,
Myelogenous, Chronic OR Myelogenous Leukemia,
Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR
Myelogenous Leukemia, Chronic OR Myeloid Leukemia,
Philadelphia-Positive OR Granulocytic Leukemia, Chronic
OR Leukemia, Myeloid, Chronic, Atypical, BCR-ABL
Negative) AND (classification OR criteria OR World Health
Organization* OR standards*) AND (sensitiv*[Title/
Abstract] OR sensitivity and specificity[MeSH Terms] OR
diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] OR
diagnostic * [MeSH:noexp] OR diagnosis,differential[MeSH
:noexp] OR diagnosis[Subheading:noexp])
PICO 2
Is there any difference in the prognosis of CML patients
with p210, e13a2(b2a2) and e14a2(b3a2) or (e1a2)p190
rearrangements?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND ((Fusion Proteins, bcr-abl AND
genetics*) OR p210 OR e13a2 OR b2a2 OR e14a2 OR
b3a2 OR p190 OR e1a2 OR Isoform*) AND (prognos*[Title/
Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract])
OR cohort[Title/Abstract])
PICO 3
At diagnosis, do the Philadelphia chromosome and the 9q
deletion have prognostic significance?